Phaseline

Targets › HPV5

HPV5: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 4; Infectious disease, Genitourinary; next expected readout Aug 2027.

Open in Phaseline: the race on HPV5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The University of Texas Medical Branch, Galveston9-valent HPV vaccine, 2 doses alternate timing
Recombinant human papillomavirus vaccine targeting 9 HPV types
HPV5, HPV6, HPV11, HPV16, HPV18Phase 4ImmunizationAug 2027
Erasmus Medical CenterGardasil 9 Suspension for Injection
Nonavalent HPV vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58
HPV5, HPV11, HPV16, HPV18Phase 4Vulvar HSILDec 2028

Conditions

Immunization (1) Vulvar HSIL (1)

Modalities

other (1), small molecule (1)

Companies

The University of Texas Medical Branch, Galveston (1) Erasmus Medical Center (1)

Related targets

HPV11 (2) HPV16 (2) HPV18 (2) HPV6 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.